As interest in lesser-known cannabinoids grows, cannabichromene, or CBC, is emerging as a promising molecule in the hemp industry. Known for its potential to provide relief beyond what CBD alone offers, CBC is gaining attention for its unique therapeutic properties. In this blog, we will explore what CBC is, how it differs from CBD, and its potential benefits. We’ll also look at how CBC could contribute to the growth of the hemp industry, particularly in wellness products and the broader trend toward using minor cannabinoids for relief.
What is CBC?
Cannabichromene (CBC) has been studied for over 50 years, yet it remains lesser-known compared to THC and CBD. Discovered in 1964 by Raphael Mechoulam and his team, CBC is the third most abundant cannabinoid in cannabis, originating from the same precursor molecule, cannabigerolic acid (CBGa), as CBD and THC. While THC and CBD dominate the spotlight, CBC holds significant potential with its promising benefits, making it an exciting area of ongoing medical research. As part of a group of over 100 cannabinoids, CBC remains an important but underexplored compound within the cannabis plant.
CBC vs CBD: What's the Difference?
Despite their structural similarities, CBD and CBC have distinct effects that set them apart, leading many to question their differences. Cannabinoids, including CBD and CBC, often work synergistically in the body, enhancing each other’s effects when found together in nature or in formulated products. While CBD is widely recognized for its broad range of benefits—from stress relief to boosting energy and overall wellness—CBC tends to provide more targeted relief, particularly for discomfort. When combined, these two cannabinoids can offer enhanced benefits, making them a powerful duo for those seeking both daily and long-term relief.
What is CBC Good For?
As with any hemp-derived compound, further research is necessary to fully understand CBC’s potential. However, early studies have shown that CBC may offer assistance with mobility issues related to discomfort in mice.(1) Additionally, research has identified that CBC interacts primarily with CB2 receptors in the human body, which are associated with the nervous system and peripheral tissue, while it shows minimal interaction with CB1 receptors, which are linked to the spinal cord and digestive tract. (2)
Consumers report enhanced relief with CBC, influencing some major changes within the hemp industry. The growing demand for CBC’s unique properties is prompting a shift away from a focus solely on CBD and THC, as more individuals seek alternatives that better address their needs. This shift is encouraging the industry to explore and develop a broader range of cannabinoid-based products, with CBC emerging as a leading option.
Featured Category
CBC for Relief
CBC provides targeted relief from discomfort, offering a natural way to manage everyday aches and support recovery.
The Future of CBC in the Hemp Industry
The expansion of cannabinoid products goes beyond providing consumers with alternative wellness options; it signals a broader shift in the hemp industry, allowing for greater cultivation and extraction efforts tailored to meet the demand for CBC and other niche cannabinoids. As regulations evolve and the industry embraces more specialized compounds, the potential for cannabinoids like CBC to offer tailored, natural alternatives to traditional medications will continue to grow.
The rise of cannabichromene (CBC) reflects a broader movement within the hemp industry to explore and harness the therapeutic potential of lesser-known cannabinoids. As research into CBC and other minor cannabinoids advances, we are likely to see a continued expansion of hemp-derived products designed to meet diverse consumer needs. However, while the promise of CBC is compelling, it is essential to approach these products with caution. Always consult a healthcare professional before incorporating CBC or any hemp-based product into your wellness routine, especially if you are considering alternatives to traditional treatments.
1 Izzo AA, Capasso R, Aviello G, Borrelli F, Romano B, Piscitelli F, Gallo L, Capasso F, Orlando P, Di Marzo V. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol. 2012 Jun;166(4):1444-60. DOI: 10.1111/j.1476-5381.2012.01879.x. PMCID: PMC3417459.
2 Udoh M, Santiago M, Devenish S, McGregor IS, Connor M. Cannabichromene is a cannabinoid CB2 receptor agonist. Br J Pharmacol. 2019 Dec;176(23):4537-4547. DOI: 10.1111/bph.14815. PMCID: PMC6932936.
